Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | CASP3 | P42574 | 2/20 | 0.52 |
| ▸ | MDM4 | O15151 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.48 |
| ▸ | TLR2 | O60603 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12574034 | 1.00 | KMT2A (0.52) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL12677657 | 1.00 | KMT2A (0.52) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL1784562 | 0.90 | TLR2 (0.50) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL10138748 | 0.90 | TLR2 (0.50) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL13688703 | 0.90 | TLR2 (0.50) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL118051 | 0.90 | MDM4 (0.60) | KMT2ACASP3MDM4TP53MDM2 | |
| SCHEMBL16000763 | 0.90 | KMT2A (0.52) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL5839367 | 0.90 | KMT2A (0.52) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL7391110 | 0.90 | KMT2A (0.52) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL31675022 | 0.90 | MDM4 (0.60) | KMT2ACASP3MDM4TP53MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2362866-B1 | ISOPRENYL COMPOUNDS AND METHODS THEREOF | SIGNUM BIOSCIENCES INC (US) | 2015-07-08 | — | — | EP | disclosed |
| US-8580746-B2 | Amide linkage cyclic natriuretic peptide constructs | PALATIN TECHNOLOGIES, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580747-B2 | Cyclic natriuretic peptide constructs | PALATIN TECHNOLOGIES, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8114844-B2 | Linear and cyclic melanocortin receptor-specific peptidomimetics | PALATIN TECHNOLOGIES, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-7964181-B2 | Amino acid surrogates for peptidic constructs | PALATIN TECHNOLOGIES, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7956216-B2 | Benzoyl urea derivatives mimicing BH3-only proteins, able to interact with a Bcl-2 protein | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2011-06-07 | — | — | US | disclosed |
| US-7910609-B2 | Inhibitors of integrin alpha2beta1 with modified urea moiety | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2011-03-22 | — | — | US | disclosed |
| US-7795221-B2 | Linear natriuretic peptide constructs | PALATIN TECHNOLOGIES, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20100075895-A1 | Cyclic Natriuretic Peptide Constructs | PALATIN TECHNOLOGIES, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100035821-A1 | Amide Linkage Cyclic Natriuretic Peptide Constructs | PALATIN TECHNOLOGIES, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| US-7622440-B2 | Cyclic natriuretic peptide constructs | PALATIN TECHNOLOGIES, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20090197861-A1 | INHIBITORS OF INTEGRIN ALPHA2BETA1 WITH MODIFIED UREA MOIETY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-06 | — | — | US | disclosed |
| US-20090082372-A1 | Arylmethylene Substituted N-Acyl-Beta-Amino Alcohols | BAYER SCHERING PHARMA AG (DE) | 2009-03-26 | — | — | US | disclosed |
| US-20090069224-A1 | Linear and Cyclic Melanocortin Receptor-Specific Peptidomimetics | PALATIN TECHNOLOGIES, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-20080153802-A1 | Alpha-helical mimetics | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2008-06-26 | — | — | US | disclosed |
| US-20070265206-A1 | Cyclic Natriuretic Peptide Constructs | PALATIN TECHNOLOGIES, INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070260040-A1 | Amino Acid Surrogates for Peptidic Constructs | PALATIN TECHNOLOGIES, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070232546-A1 | Linear Natriuretic Peptide Constructs | PALATIN TECHNOLOGIES, INC. (US) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265206-A1 | Cyclic Natriuretic Peptide Constructs | NPR1, NPR3, NPPA | KMT2A 3394/4885CASP3 4353/4885MDM4 4632/4885 |
| US-20070260040-A1 | Amino Acid Surrogates for Peptidic Constructs | ARGLU1, ARG1, QRFPR | KMT2A 1061/4885CASP3 3729/4885MDM4 2560/4885 |
| US-20090069224-A1 | Linear and Cyclic Melanocortin Receptor-Specific Peptidomimetics | MC1R, MC3R, MC5R | KMT2A 1770/4885CASP3 4727/4885MDM4 4268/4885 |
| US-20080153802-A1 | Alpha-helical mimetics | BID, BAX, BAD | KMT2A 2959/4885CASP3 21/4885MDM4 550/4885 |
| US-20100035821-A1 | Amide Linkage Cyclic Natriuretic Peptide Constructs | NPR1, NPR3, NPPA | KMT2A 3187/4885CASP3 4143/4885MDM4 4876/4885 |
| US-20070232546-A1 | Linear Natriuretic Peptide Constructs | NPR1, NPR3, NPPA | KMT2A 2397/4885CASP3 4168/4885MDM4 4792/4885 |
| US-20100075895-A1 | Cyclic Natriuretic Peptide Constructs | NPR1, NPR3, NPPA | KMT2A 3394/4885CASP3 4353/4885MDM4 4632/4885 |
| US-20090082372-A1 | Arylmethylene Substituted N-Acyl-Beta-Amino Alcohols | FSHR, SHBG, NAT1 | KMT2A 331/4885CASP3 3483/4885MDM4 4701/4885 |
| US-20090197861-A1 | INHIBITORS OF INTEGRIN ALPHA2BETA1 WITH MODIFIED UREA MOIETY | ITGA2B, ITGA2, ITGB2 | KMT2A 3126/4885CASP3 3336/4885MDM4 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.